Drugs / JY306
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06837389 | Feb 2025 → Mar 2026 overdue | refractory hematologic cancer | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JY306 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06837389 ↗ |
| Modality | Cell therapy | “universal NK cell injection” NCT06837389 ↗ |